118 related articles for article (PubMed ID: 28523881)
1. Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib.
Finelt N; Lulla RR; Melin-Aldana H; Ruth JS; Lin FY; Su JM; Pourciau CY; Hunt RD; Kenner-Bell BM
Pediatr Dermatol; 2017 May; 34(3):337-341. PubMed ID: 28523881
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.
West ES; Williams VL; Morelli JG
Pediatr Dermatol; 2015; 32(1):153-4. PubMed ID: 24602192
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-induced neutrophilic panniculitis.
Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
[TBL] [Abstract][Full Text] [Related]
4. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
7. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
Kim GH; Levy A; Compoginis G
J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
9. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
[No Abstract] [Full Text] [Related]
10. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
[TBL] [Abstract][Full Text] [Related]
11. Vasculitis and panniculitis associated with vemurafenib.
Novoa RA; Honda K; Koon HB; Gerstenblith MR
J Am Acad Dermatol; 2012 Dec; 67(6):e271-2. PubMed ID: 23158633
[No Abstract] [Full Text] [Related]
12. Comment on "Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib".
Bhat T; Rosman IS; Coughlin CC
Pediatr Dermatol; 2018 Mar; 35(2):287-288. PubMed ID: 29575074
[No Abstract] [Full Text] [Related]
13. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.
Pattanaprichakul P; Tetzlaff MT; Lapolla WJ; Torres-Cabala CA; Duvic M; Prieto VG; Tsai KY; Curry JL
J Cutan Pathol; 2014 Mar; 41(3):326-8. PubMed ID: 24372055
[No Abstract] [Full Text] [Related]
14. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN
Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
16. Panniculitis in patients treated with BRAF inhibitors: a case series.
Choy B; Chou S; Anforth R; Fernández-Peñas P
Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
[TBL] [Abstract][Full Text] [Related]
17. Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis.
Chen L; Hsi AC; Kothari A; Dehner LP; Hayashi RJ; Coughlin CC
Pediatr Dermatol; 2018 Nov; 35(6):e402-e403. PubMed ID: 30216522
[TBL] [Abstract][Full Text] [Related]
18. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib-induced progression of breast cancer: a case report and review of the literature.
Novik AV; Protsenko SA; Baldueva IA; Ivantsov AO; Nekhaeva TL; Akhaeva ZY; Yanus GA; Iyevleva AG; Imyanitov EN
Target Oncol; 2016 Apr; 11(2):235-8. PubMed ID: 26264150
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
